These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33201284)

  • 1. Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis.
    Muglia R; Simonelli M; Pessina F; Morenghi E; Navarria P; Persico P; Lorenzi E; Dipasquale A; Grimaldi M; Scorsetti M; Santoro A; Politi LS
    Eur Radiol; 2021 Jun; 31(6):4079-4086. PubMed ID: 33201284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The possible relation between temporal muscle mass and glioblastoma multiforme prognosis via sarcopenia perspective.
    Sütcüoğlu O; Erdal ZS; Akdoğan O; Çeltikçi E; Özdemir N; Özet A; Uçar M; Yazıcı O
    Turk J Med Sci; 2023 Feb; 53(1):413-419. PubMed ID: 36945944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial.
    Furtner J; Genbrugge E; Gorlia T; Bendszus M; Nowosielski M; Golfinopoulos V; Weller M; van den Bent MJ; Wick W; Preusser M
    Neuro Oncol; 2019 Dec; 21(12):1587-1594. PubMed ID: 31369680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel radiographic marker of sarcopenia with prognostic value in glioblastoma.
    Huq S; Khalafallah AM; Ruiz-Cardozo MA; Botros D; Oliveira LAP; Dux H; White T; Jimenez AE; Gujar SK; Sair HI; Pillai JJ; Mukherjee D
    Clin Neurol Neurosurg; 2021 Aug; 207():106782. PubMed ID: 34186275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of reduced temporal muscle thickness and systemic muscle loss in newly diagnosed glioblastoma patients.
    Ten Cate C; Huijs SMH; Willemsen ACH; Pasmans RCOS; Eekers DBP; Zegers CML; Ackermans L; Beckervordersandforth J; van Raak EPM; Anten MHME; Hoeben A; Postma AA; Broen MPG
    J Neurooncol; 2022 Dec; 160(3):611-618. PubMed ID: 36394717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases.
    Furtner J; Berghoff AS; Albtoush OM; Woitek R; Asenbaum U; Prayer D; Widhalm G; Gatterbauer B; Dieckmann K; Birner P; Aretin B; Bartsch R; Zielinski CC; Schöpf V; Preusser M
    Eur Radiol; 2017 Aug; 27(8):3167-3173. PubMed ID: 28050694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071-22072 and CORE Trials.
    Furtner J; Weller M; Weber M; Gorlia T; Nabors B; Reardon DA; Tonn JC; Stupp R; Preusser M;
    Clin Cancer Res; 2022 Jan; 28(1):129-136. PubMed ID: 34667022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between temporal muscle thickness and clinical outcomes in patients with newly diagnosed glioblastoma.
    An G; Ahn S; Park JS; Jeun SS; Hong YK
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):901-909. PubMed ID: 32929611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is temporal muscle thickness a survival predictor in newly diagnosed glioblastoma multiforme?
    Yesil Cinkir H; Colakoglu Er H
    Asia Pac J Clin Oncol; 2020 Oct; 16(5):e223-e227. PubMed ID: 32762134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal muscle thickness as an independent prognostic marker in glioblastoma patients-a systematic review and meta-analysis.
    Sadhwani N; Aggarwal A; Mishra A; Garg K
    Neurosurg Rev; 2022 Dec; 45(6):3619-3628. PubMed ID: 36350492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
    Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
    Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
    J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between prognosis and temporal muscle thickness in 102 patients with glioblastoma.
    Tang J; Dong Z; Yang L; Yang P; Zhao W; Deng L; Xue J; Cui Y; Li Q; Tang L; Sheng J; Zhang Y; Zhang H; Chen T; Dong B; Lv X
    Sci Rep; 2024 Jun; 14(1):13958. PubMed ID: 38886495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma.
    Choi YS; Ahn SS; Kim DW; Chang JH; Kang SG; Kim EH; Kim SH; Rim TH; Lee SK
    Radiology; 2016 Oct; 281(1):175-84. PubMed ID: 27120357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of temporal muscle thickness, a novel radiographic marker of sarcopenia, in patients with brain tumor: A systematic review and meta-analysis.
    Yang YW; Ming Yang ; Zhou YW; Xia X; Jia SL; Zhao YL; Zhou LX; Cao Y; Ge ML
    Nutrition; 2023 Aug; 112():112077. PubMed ID: 37236042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
    Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
    J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases.
    Furtner J; Berghoff AS; Schöpf V; Reumann R; Pascher B; Woitek R; Asenbaum U; Pelster S; Leitner J; Widhalm G; Gatterbauer B; Dieckmann K; Höller C; Prayer D; Preusser M
    J Neurooncol; 2018 Oct; 140(1):173-178. PubMed ID: 30008154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.
    Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T
    J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.